Literature DB >> 2803729

Altered expression of leucocyte sialoglycoprotein in Wiskott-Aldrich syndrome is associated with a specific defect in O-glycosylation.

W L Greer1, E Higgins, D R Sutherland, A Novogrodsky, I Brockhausen, M Peacocke, L A Rubin, M Baker, J W Dennis, K A Siminovitch.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is an X-linked immune deficiency disorder characterized clinically by both lymphocyte and platelet dysfunction. Studies of WAS T lymphocytes have revealed deficient or defective cell surface expression of the highly O-glycosylated leucocyte sialoglycoprotein CD43. To further elucidate the basis for, and functional relevance of, CD43 modifications on WAS lymphocytes, we have studied lymphocytes from two WAS patients with regard to membrane glycoprotein profile and mitogen-induced proliferative responses. CD43 was found to be either absent or altered in size on peripheral blood lymphocytes and lectin-stimulated T cells from both patients. Compared with control cells, the WAS lymphocytes displayed reduced, but measurable proliferative responses to lectins and neuraminidase/galactose oxidase, and virtually no response to periodate, a mitogenic agent which targets sialic acid residues on membrane glycoproteins such as CD43. Analysis of activities of three glycosyltransferases involved in O-glycosylation revealed marked reduction in the level of activity of UDP-N-acetylglucosamine: Gal beta 1-3GalNAc-R beta-1,6-N-acetylglucosamine (beta-1,6-GlcNAc) transferase in one WAS patient and no detectable activity of this enzyme in a second. beta-1,6-GlcNAc transferase activity has recently been shown to increase during T cell activation coincident with changes in the O-linked glycans on CD43. A selective reduction of this glycosyltransferase in WAS lymphocytes suggests that O-linked oligosaccharides may be important to the structure of membrane glycoproteins involved in lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803729     DOI: 10.1139/o89-081

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  13 in total

1.  Development of monoclonal antibodies against bovine mucin core 2 beta6 N-acetylglucosaminyltransferase.

Authors:  C M Li; N Joshee; K B Adler; P W Cheng
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

2.  Mutations Affecting O-Glycosylation in Chlamydomonas reinhardtii Cause Delayed Cell Wall Degradation and Sex-Limited Sterility.

Authors:  O. Vallon; F. A. Wollman
Journal:  Plant Physiol       Date:  1995-06       Impact factor: 8.340

Review 3.  Novel clearance mechanisms of platelets.

Authors:  Renata Grozovsky; Karin M Hoffmeister; Hervé Falet
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 4.  Wiskott-Aldrich syndrome: a multidisciplinary disease.

Authors:  G R Standen
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

Review 5.  Genetics of human X-linked immunodeficiency diseases.

Authors:  R W Hendriks; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 6.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Studies of the expression of the Wiskott-Aldrich syndrome protein.

Authors:  D M Stewart; S Treiber-Held; C C Kurman; F Facchetti; L D Notarangelo; D L Nelson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  The Wiskott-Aldrich syndrome: refinement of the localization on Xp and identification of another closely linked marker locus, OATL1.

Authors:  W L Greer; M Peacocke; K A Siminovitch
Journal:  Hum Genet       Date:  1992-02       Impact factor: 4.132

9.  Differential epitope expression of Ly-48 (mouse leukosialin).

Authors:  C M Baecher-Allan; J D Kemp; K S Dorfman; R K Barth; J G Frelinger
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

10.  Discovering the Cause of Wiskott-Aldrich Syndrome and Laying the Foundation for Understanding Immune Cell Structuring.

Authors:  Emily M Mace; Jordan S Orange
Journal:  J Immunol       Date:  2018-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.